Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.36 |
| ▸ | NPY1R | P25929 | 5/20 | 0.35 |
| ▸ | NPY4R | P50391 | 5/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | GLP1R | P43220 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702633 | 0.92 | TRPV1 (0.38) | FURINNPY1RNPY4RNPY5RNPY2R | |
| SCHEMBL22702532 | 0.90 | FURIN (0.38) | FURINNPY1RNPY4RHTTOPRK1 | |
| SCHEMBL25826704 | 0.87 | SIRT2 (0.37) | FURINNPY1RNPY4RHTT | |
| SCHEMBL22138371 | 0.86 | FURIN (0.44) | FURINNPY1RNPY4RHTTGLP1R | |
| SCHEMBL24591729 | 0.86 | GLP1R (0.39) | FURINNPY1RNPY4RNPY5RNPY2R | |
| SCHEMBL19359701 | 0.84 | FURIN (0.39) | FURINNPY1RNPY4RNPY5RNPY2R | |
| SCHEMBL22702534 | 0.84 | TRPV1 (0.39) | FURINNPY1RNPY4RNPY5RNPY2R | |
| SCHEMBL22702667 | 0.83 | FURIN (0.40) | FURINNPY1RNPY4RNPY5RNPY2R | |
| SCHEMBL24829575 | 0.83 | SIRT1 (0.41) | FURINHTT | |
| SCHEMBL21153498 | 0.83 | SIRT2 (0.38) | FURINNPY1RNPY4RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | FURIN 826/4885NPY1R 3105/4885NPY4R 2169/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | FURIN 794/4885NPY1R 2542/4885NPY4R 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.